What’s new

• RPG Life Sciences exclusively markets Naprosyn ES, a first-in-India naproxen-esomeprazole combo.
• Product co-developed and supplied by Archerchem; RPG handles pan-India distribution.
• No financial guidance provided; launch is an incremental addition for a ₹707 cr revenue firm.

Why it matters

RPG Life Sciences, with zero debt and a 74.5% PAT drop, needs niche launches to revive momentum. Naprosyn ES addresses a specific need but without revenue guidance, it is a modest portfolio move.

What we’re watching

• Whether RPG quantifies sales impact on future earnings calls.
• Supply chain execution by Archerchem given co-development.
• Any competitive responses from peers with similar combos.

The full read

RPG Life Sciences has launched Naprosyn ES, a first-in-India fixed-dose combination of naproxen and esomeprazole, in partnership with Archerchem Healthcare. RPG will handle exclusive marketing and distribution across India, while Archerchem supplies the co-developed product. The combination targets patients on long-term NSAID therapy who need gastroprotection, drawing on the strong brand recall of the legacy Naprosyn franchise. Not yet quantified. For RPG, with annual revenue of ₹707 crore and zero debt, this is an incremental addition to its branded chronic therapy portfolio. The company's recent PAT decline of 74.5% shows the need for such niche launches. But without any revenue guidance or peak sales estimates, the event remains a strategic rather than financial catalyst. The product is now available nationwide.

Primary source: BSE · NSE